Orgenesis Company Overview
About Orgenesis
Orgenesis (NASDAQ:ORGS) is a pioneering company focused on the development, manufacturing, and processing of cell and gene therapies. They aim to revolutionize personalized medicine with a unique Therapeutic Platform, offering a range of services including point-of-care cell therapy treatments. The company is at the forefront of providing innovative solutions that could potentially transform the treatment of a wide array of diseases. Key projects involve developing technologies that enable hospitals and healthcare systems to process and administer therapies onsite, dramatically changing the current centralized production model. Orgenesis is dedicated to making life-saving treatments more accessible and affordable, with the ultimate goal of improving patient outcomes worldwide.
Snapshot
Operations
Produtos e/ou serviços de Orgenesis
- Cell-gene therapies platform for accelerating end-to-end therapies development.
- Automated, closed cell processing units enabling local production of cell therapies.
- Point-of-Care Cell Therapy Centers partnership model, expanding global access.
- POCare Network, a collaborative initiative for integrating therapies within healthcare systems.
- Biotech Mobile Processing Units and Labs for onsite cell therapy manufacturing.
- Development of a proprietary therapeutic pipeline focusing on diabetes and related diseases.
equipe executiva do Orgenesis
- Ms. Vered Caplan M.Sc.Chairperson of the Board, CEO & President
- Prof. Sarah Ferber Ph.D.Founder & Chief Scientific Officer
- Mr. Victor MillerCFO, Secretary & Treasurer
- Dr. Shimon Hassin Ph.D.Chief Technology Officer